Peregrine Pharmaceuticals (NASDAQ:PPHM) Earns Daily Coverage Optimism Score of 0.06

News headlines about Peregrine Pharmaceuticals (NASDAQ:PPHM) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Peregrine Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.2869263751839 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s analysis:

PPHM has been the topic of a number of recent research reports. Zacks Investment Research downgraded Peregrine Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Noble Financial reissued a “buy” rating on shares of Peregrine Pharmaceuticals in a research report on Monday, July 31st. ValuEngine raised Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Finally, BidaskClub raised Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $5.25.

Shares of Peregrine Pharmaceuticals (NASDAQ PPHM) opened at 3.23 on Friday. The firm’s 50-day moving average price is $4.28 and its 200-day moving average price is $1.53. Peregrine Pharmaceuticals has a 12-month low of $1.97 and a 12-month high of $5.78. The firm’s market capitalization is $145.57 million.

Peregrine Pharmaceuticals (NASDAQ:PPHM) last announced its earnings results on Friday, July 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.09. Peregrine Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 48.86%. The business had revenue of $17.90 million for the quarter, compared to the consensus estimate of $22.57 million. During the same period in the prior year, the business posted ($0.05) earnings per share. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. Equities analysts predict that Peregrine Pharmaceuticals will post ($0.40) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Peregrine Pharmaceuticals (NASDAQ:PPHM) Earns Daily Coverage Optimism Score of 0.06” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/peregrine-pharmaceuticals-nasdaqpphm-earns-daily-news-impact-score-of-0-06-updated.html.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

Insider Buying and Selling by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply